Compare NNI & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNI | APGE |
|---|---|---|
| Founded | 1978 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.7B |
| IPO Year | 2003 | 2023 |
| Metric | NNI | APGE |
|---|---|---|
| Price | $141.14 | $84.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $140.00 | $109.67 |
| AVG Volume (30 Days) | 99.6K | ★ 549.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 134.86 | N/A |
| EPS | ★ 11.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.28 | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | $11.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $105.45 | $34.34 |
| 52 Week High | $144.38 | $95.32 |
| Indicator | NNI | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 51.42 |
| Support Level | $128.24 | $73.06 |
| Resistance Level | $142.71 | $84.56 |
| Average True Range (ATR) | 3.30 | 3.49 |
| MACD | -0.09 | -1.06 |
| Stochastic Oscillator | 68.82 | 26.26 |
Nelnet Inc is a United States based company engaged in these four reportable segments; Loan Servicing and Systems focuses on student and consumer loan origination services and servicing, loan origination and servicing-related technology solutions, and outsourcing business services; Education Technology Services and Payments segment provides education services, payment technology, and community management solutions for K-12 schools, institutions, churches, and businesses; Asset Generation and Management segment includes the acquisition and management of student and other loan assets; and Nelnet Bank focuses on the private education and unsecured consumer loan markets. Maximum revenue for the company is generated from its Education Technology Services and Payments segment.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.